Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
In development [GID-TA10026] Expected publication date: TBC
Search results
599 results
-
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: 22 June 2022
-
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]
In development [GID-TA10732] Expected publication date: 21 September 2022
-
Therapeutics for people with COVID-19 [ID4038]
In development [GID-TA10936] Expected publication date: TBC
-
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer [ID3929]
In development [GID-TA10825] Expected publication date: 29 July 2022
-
Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379) [ID4062]
In development [GID-TA10975] Expected publication date: 01 March 2023
-
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]
In development [GID-TA10498] Expected publication date: TBC
-
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer [ID1546]
In development [GID-TA10417] Expected publication date: 29 June 2022
-
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]
In development [GID-TA10805] Expected publication date: 12 October 2022
-
Romosozumab for treating severe osteoporosis [ID3936]
In development [GID-TA10828] Expected publication date: TBC
-
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]
In development [GID-TA10824] Expected publication date: 01 March 2023
-
Efgartigimod for treating generalised myasthenia gravis [ID4003]
In development [GID-TA10986] Expected publication date: TBC
-
Ravulizumab for treating refractory antibody positive generalised myasthenia gravis [ID4019]
In development [GID-TA10987] Expected publication date: TBC
-
Voxelotor for treating sickle cell disease [ID1403]
In development [GID-TA10505] Expected publication date: 01 March 2023
-
Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson's disease [ID4005]
In development [GID-TA10983] Expected publication date: TBC
-
Baricitinib for treating severe alopecia areata ID3979
In development [GID-TA10941] Expected publication date: TBC
-
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
In development [GID-TA10948] Expected publication date: TBC
-
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]
In development [GID-TA10785] Expected publication date: 16 November 2022
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
In development [GID-TA10632] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]
In development [GID-TA10784] Expected publication date: TBC
-
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]
In development [GID-TA10600] Expected publication date: 08 June 2022
-
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer [ID4056]
In development [GID-TA11012] Expected publication date: TBC
-
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]
In development [GID-TA10990] Expected publication date: TBC
-
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies [ID3950]
In development [GID-TA10849] Expected publication date: 19 July 2023
-
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 22 June 2022
-
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (CDF review of TA578) [ID3885]
In development [GID-TA10894] Expected publication date: 27 June 2022
-
Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]
In development [GID-TA10692] Expected publication date: 04 January 2023
-
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (Review of TA619) [ID3779]
In development [GID-TA10901] Expected publication date: 23 November 2022
-
Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
In development [GID-TA10730] Expected publication date: 23 November 2022
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: 23 November 2022
-
Ritlecitinib for treating moderate to severe alopecia areata in people 12 years and over [ID4007]
In development [GID-TA11037] Expected publication date: TBC
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]
In development [GID-TA10802] Expected publication date: TBC
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]
In development [GID-TA10820] Expected publication date: 14 September 2022
-
Peezy Midstream for urine collection (MT446)
In development [GID-MT538] Expected publication date: TBC
-
Skin abscess: antimicrobial prescribing
In development [GID-NG10163] Expected publication date: TBC
-
Conjunctivitis: antimicrobial prescribing
In development [GID-NG10166] Expected publication date: TBC
-
Blepharitis: antimicrobial prescribing
In development [GID-NG10168] Expected publication date: TBC
-
Stye: antimicrobial prescribing
In development [GID-NG10167] Expected publication date: TBC
-
MRI guided focussed ultrasound for chronic pain
In development [GID-IP1043] Expected publication date: TBC
-
Peroral endoscopic myotomy (POEM) for achalasia
In development [GID-IP1229] Expected publication date: TBC
-
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
In development [GID-IP1170] Expected publication date: TBC
-
Implantable Vagus Nerve Stimulator in Heart Failure
In development [GID-IP1145] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
In development [GID-TA10377] Expected publication date: TBC
-
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
In development [GID-TA10539] Expected publication date: TBC
-
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
In development [GID-TA10635] Expected publication date: TBC
-
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455
In development [GID-TA10356] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: TBC
-
Systemic lupus erythematosus - prasterone [ID392]
In development [GID-TAG373] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC